ER Dysfunction and Protein Folding Stress in ALS by Matus, Soledad et al.
 ER Dysfunction and Protein Folding Stress in ALS
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Matus, Soledad, Vicente Valenzuela, Danilo B. Medinas, and
Claudio Hetz. 2013. “ER Dysfunction and Protein Folding Stress
in ALS.” International Journal of Cell Biology 2013 (1): 674751.
doi:10.1155/2013/674751.
http://dx.doi.org/10.1155/2013/674751.
Published Version doi:10.1155/2013/674751
Accessed February 19, 2015 2:58:26 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879275
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAA
Hindawi Publishing Corporation
International Journal of Cell Biology
Volume 2013, Article ID 674751, 12 pages
http://dx.doi.org/10.1155/2013/674751
Review Article
ER Dysfunction and Protein Folding Stress in ALS
Soledad Matus,1 Vicente Valenzuela,2,3 Danilo B. Medinas,2,3 and Claudio Hetz2,3,4
1 Neurounion Biomedical Foundation, Santiago, Chile
2 Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile
3 Center for Molecular Studies of the Cell, Program of Cellular and Molecular Biology,
Institute of Biomedical Sciences, University of Chile, Santiago, Chile
4Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA
Correspondence should be addressed to Soledad Matus; soledad.matus@neurounion.com
and Claudio Hetz; chetz@hsph.harvard.edu
Received 22 May 2013; Accepted 2 September 2013
Academic Editor: Roberto Chiesa
Copyright © 2013 Soledad Matus et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Amyotrophic lateral sclerosis (ALS) is the most frequent paralytic disease in adults. Most ALS cases are considered sporadic with
no clear genetic component. The disruption of protein homeostasis due to chronic stress responses at the endoplasmic reticulum
(ER) and the accumulation of abnormal protein inclusions are extensively described in ALS mouse models and patient-derived
tissue. Recent studies using pharmacological and genetic manipulation of the unfolded protein response (UPR), an adaptive
reaction against ER stress, have demonstrated a complex involvement of the pathway in experimental models of ALS. In addition,
quantitative changes in ER stress-responsive chaperones in body fluids have been proposed as possible biomarkers to monitor the
disease progression. Here we review most recent advances attributing a causal role of ER stress in ALS.
1. Introduction
Several neurodegenerative disorders, including Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, and amy-
otrophic lateral sclerosis (ALS), share common features,
among them the presence of abnormal protein aggregates
and the inclusions containing specificmisfolded proteins.The
presence of these abnormal protein aggregates has been tem-
porally and spatially correlated with the activation of stress
signaling pathway emerging from the endoplasmic reticu-
lum (ER), a cellular reaction named the “unfolded protein
response” (UPR). In the last years, ER stress levels and
UPR activation in neurodegenerative diseases have been
extensively studied. In this review,we focus on recent findings
placing ER stress as a key component of neurodegeneration
in ALS and discuss the different mechanisms by which the
UPR may impact disease progression and the therapeu-
tic potential of manipulating this signaling pathway in
ALS.
2. Amyotrophic Lateral Sclerosis
ALS is a progressive and deadly adult-onset motoneuron
disease characterized bymuscle weakness, spasticity, atrophy,
paralysis, and premature death [1, 2]. The pathological hall-
mark of ALS is the selective degeneration of motoneurons in
the spinal ventral horn, most of brainstem nuclei, and cere-
bral cortex. ALS has an average age of onset around 50 years
and estimated incidence of 1-2 cases per 100,000 individuals
[1]. ALS is presently incurable with a mean survival time of
1–5 years from diagnosis, often resulting in fatal respiratory
dysfunction. The majority of ALS patients lack a defined
hereditary genetic component and are considered sporadic
(sALS), while approximately 10% of cases are familial (fALS)
[1].Themost common genetic causes of fALS are the recently
defined hexanucleotide repeat expansion in the intronic
region of C9orf72 and the mutations in the gene encoding
cytosolic superoxide dismutase 1 (SOD1), which together
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account for around 50% of fALS cases. Many other disease-
causative genes have been identified, including TAR DNA-
binding protein (TARDBP or TDP-43), fused in sarcoma
(FUS/TLS), vesicle-associated membrane protein-associated
protein B (VAPB), among others [1, 3]. All of these mutations
trigger the aggregation of the affected protein, which is
associated in part with a gain of neurotoxic activity and
possibly neuroinflammatory processes. Overexpression of
human fALS-linked SOD1 and TDP-43mutants inmice reca-
pitulates essential features of the humanpathology, provoking
age-dependent protein aggregation, paralysis, motoneuron
degeneration, and muscle atrophy (reviewed in [2, 4]). Stud-
ies in these mouse models of ALS have revealed valuable
information about the molecular bases of the disease and,
in particular, how the presence of these mutant proteins can
trigger ER stress.
Since the same groups of neurons are affected in sALS
and fALS leading to a similar pathology, it is predicted that
therapies in mutant ALS genetic models may translate to
sporadic ALS. In fact, accumulation of misfolded oligomers
or protein inclusions containing wild-type (WT) TDP-43,
FUS, or SOD1 has been recently shown to be a prominent
histopathological feature of sALS (see examples in [5, 6]).
Different pathogenicmechanisms have been proposed inALS
including neuroinflammation, glial activation, neuronal traf-
ficking problems, excitotoxicity, mitochondrial dysfunction,
and oxidative stress (reviewed in [2, 4]). Interestingly, accu-
mulating evidence from several laboratories points towards a
key role of alterations of protein homeostasis in the disease
process, in both sALS and fALS (reviewed in [7–9]). In this
context, ER stress is emerging as an interesting target for the
development of prototypic treatments to ALS. In the next
sections, we provide a comprehensive update of the work
implicating ER stress to ALS pathogenesis.
3. ER Stress and UPR Signaling: An Overview
The ER is the first compartment where secreted and mem-
brane proteins are synthesized and folded. For this process,
a large and efficient network of chaperones, foldases, and co-
factors are expressed at the ER to promote folding andprevent
abnormal aggregation of proteins. The ER also operates as
a major intracellular calcium store and plays a crucial role
in the synthesis of lipids. A number of stress conditions
can interfere with the function of this organelle and cause
abnormal oxidative folding at the ER lumen, resulting in a
cellular condition termed “ER stress” [10]. ER stress engages
the unfolded protein response (UPR), an integrated sig-
nal transduction pathway that reestablish homeostasis by
increasing the protein folding capacity and quality control
mechanisms of the ER [11]. Conversely, chronic ER stress
results in apoptosis of irreversibly damaged cells through
diverse complementary mechanisms [12].
TheUPR is activated by threemain stress sensors, includ-
ing PKR-like ER kinase (PERK), inositol-requiring trans-
membrane kinase/endonuclease (IRE1), and activating tran-
scription factor 6 (ATF6). IRE1 is an ER located kinase and
endoribonuclease conserved from yeast to humans. Upon
UPR activation, IRE1 initiates the splicing of the mRNA
encoding the transcriptional factor X-Box-binding protein
1 (XBP1), converting it into a potent activator of multiple
UPR-responsive genes (termedXBP1s) [13–15]. XBP1s control
the expression of genes involved in protein folding, secre-
tion, protein quality control, and ER-associated degradation
(ERAD) [16, 17]. IRE1𝛼 also regulates other signaling events
including the downstream activation of JNK, modulating
apoptosis and autophagy levels. In addition, IRE1 is able to
degrade a subset of mRNA through its RNAse activity on a
tissue specific manner (reviewed in [18]).
The activation of the stress sensor PERK reduces pro-
tein translation into the ER by phosphorylating eukaryotic
initiation factor 2 alpha (eIF2𝛼), which in turns contributes
to decrease the misfolded protein overload [19]. The phos-
phorylation of eIF2𝛼 also allows the expression of activating
transcription factor 4 (ATF4), a key factor that upregulates
a subset of UPR-targeted genes involved in amino acid and
redox metabolism, autophagy, protein folding, and apoptosis
[20–22] (reviewed in [11, 23]). Among them, CHOP is a
key mediator of apoptosis under ER stress [11, 23], which
may operate by controlling the expression of several pro-
apoptotic members of the BCL2 family of proteins (i.e., BIM
and PUMA) in addition to GADD45 [24]. Sustained PERK
signaling also contributes to apoptosis by enhancing oxida-
tive stress and by resuming protein synthesis after prolonged
ER stress [25–27].
ATF6 is activated at the ER and then translocates to the
Golgi apparatus where it is processed, releasing the cytosolic
domain that acts as a transcription factor [11]. ATF6 controls
a subset of UPR-targeted genes related to protein folding
and quality control mechanisms [28, 29]. Overall, UPR
signaling responses integrate information about the nature
and intensity of the stress stimuli to modulate the expression
of a large spectrum of partially overlapping target genes that
orchestrate adaptation to stress or trigger cell death programs
[12].
4. ER Stress Signaling in sALS
The involvement of ER stress in sporadic ALS can be inferred
from correlative studies in human postmortem tissue. Many
reports have identified the upregulation and activation of
the three main UPR signaling branches, in addition to the
description of elevated levels of ER chaperones and cell death
signals linked to ER stress [30–34] (see examples in Figure 1).
Ilieva et al. showed enhanced phosphorylation of eIF2𝛼 and
increased levels of the ER foldase PDIA1 along with elevated
levels of oxidized proteins in spinal cord of sporadic ALS
patients [32]. We also reported the upregulation of the ER
foldase ERp57 in sALS and fALS, in addition to the expression
of XBP1s and ATF4 [31]. Other groups also described the up-
regulation of CHOP in sALS [30, 33] (Figure 1(d)). In line
with the aforementioned observations, augmented levels of
PERK, ATF6, and IRE1 have been found [30] (Figure 1(c)).
Additional support for the importance of ER stress in
ALS pathogenesis comes from ultrastructural studies [35,
36]. Oyanagi et al. detected distended and fragmented ER
cisternae in the affected cells of the anterior horn of the
spinal cord [35]. In a recent study, Sasaki observed an
International Journal of Cell Biology 3
SMI-32
Control
sALS 1
sALS 2
PDI
(a)
Control
fALS
FUS PDI
(b)
ATF6 Merge
NTG
NTG
NF-H DAPI
SOD1G93A
SOD1G93A
SOD1WT
(c)
Control            sALS
SOD1G93A
A B
C D
E F
(d)
PDI VAPB GFP/PDI/VAPB
VAPBP56S
(e)
Figure 1:UPR activation inALShuman samples andmousemodels of the disease. Several examples of published data indicating the activation
of the UPR in SALS human samples and animal models. (a) Immunostaining of spinal cord motoneurons with the neurofilament marker
SMI-32 showing PDIA1 (PDI) overexpression in samples from two sporadic ALS patients (sALS) compared with healthy subjects. Scale bar,
10𝜇m (fromAtkin et al. [30]). (b) Immunohistochemistry of spinal cord section from a familial ALS patient (fALS) with a FUSmutation.The
colocalization of FUS protein (left panel) and PDIA1 (PDI) protein (right panel) is indicated with black arrows. Scale bar, 40𝜇m (from Farg
et al. [92]). (c) Left panel, immunodetection of the UPR sensor ATF6 (green), neurofilament (NF-H, red), and DAPI (blue) in spinal cord
sections from SOD1G93A mutant mice and nontransgenic control animals (NTG). Scale bar, 20 𝜇m. Right panel, SOD1 protein detection in ER
lumen by immunoelectron microscopy in SOD1G93A mutant, SOD1 wild-type (SOD1WT), and nontransgenic (NTG) mice. Scale bar, 50 nm
(from Kikuchi et al. [38]). (d) Left panel, CHOP positive cells detected in spinal cord sections from human sporadic ALS (sALS) patient.
Control tissue in (A), (C), and (E). Pictures derived from cervical spinal cord ((A) and (B)), thoracic spinal cord ((C) and (D)), and lumbar
spinal cord ((E) and (F)). Scale bars, 65 𝜇m. In the right panel, immunolocalization of CHOP (green) in anti-ChAT (red) positive spinal cord
motoneurons from SOD1G93A mutant mice. Scale bar: 40𝜇m.The areas with a box are shown at higher magnification. Scale bar 10 𝜇m (from
Ito et al. [33]). (e) Immunostaining of corticospinal motor neurons from 3-month-old VAPBP56S transgenic mice. Transgene detected with
GFP (green), PDIA1 (PDI) (red staining), and VAPB (blue staining). Arrowheads show neurons with accumulation of PDI and VAPB. Scale
bar: 20 𝜇m (from Aliaga et al. [50]). Copyright authorization was obtained from each journal for all images.
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increased immunostaining for GRP78 (BiP) in affected but
also normal-appearingmotor neurons from sporadic patients
[36]. Strikingly, a detailed examination of ER in normal-
appearing motor neurons by electron microscopy revealed
dilated ER lumen containing amorphous or granularmaterial
[36]. Additionally, ribosome-free membranous structures
extending from the ER membrane, electron-dense material
resembling Bunina bodies, Hirano bodies, and honeycomb-
like structures were observed in patient samples only [36].
Together, these biochemical and morphological evidence
correlate the development of ALS with the markers of ER
stress.
5. UPR Activation in
Experimental Models of ALS
Several laboratories have also shown the occurrence of ER
stress in most cellular and animal models of fALS associated
with mutations in FUS, TDP-43, SOD1, VAPB, and Ataxin-
2 (see examples in [37–50]) (Figure 1). Moreover, in addition
to ALS, disturbances in the function of the ER are thought
to contribute to cell loss in a number of important human
diseases including Parkinson’s, Huntington’s, andAlzheimer’s
disease [7, 51]. In this section, we discuss mostly in vivo
validations of a functional involvement of ER stress in ALS.
In an elegant study from Caroni’s group, a systematic
transcriptomic analysis was performed using laser dissection
of a group of neurons that die early (vulnerablemotoneurons)
during the course of the disease and a second group that is
resistant in a mutant SOD1 model of ALS [52] (Figure 4).
This study showed that only affected motoneurons of fALS
mouse models were selectively prone to undergo early and
chronic ER stress, which was the main molecular signature
identified using gene expression profile analysis. Moreover,
these changes were detected even before the earliest den-
ervation in asymptomatic animals [52]. In support of this
idea, several recent publications suggest that “stressful events”
are occurring at the intracellular and intercellular level long
before the locomotor defects and the protein aggregation are
observed. For example, spinal cord neurons from neonatal
SOD1 transgenic mice show hyperexcitability [53, 54], which
would be one of the earliest abnormalities found so far.
In addition to UPR markers, Saxena et al. also observed
that ALS vulnerable neurons specifically engage stress-
management pathways such as protein ubiquitination and
hypoxia-related genes, several weeks before this happens in
resistant motoneurons [52]. Furthermore, activation of the
UPR in vulnerable motoneurons coincides with the activa-
tion of microglia [52] (Figure 4(a)). It is unclear whether
resistant motoneurons are protected due to differential dis-
ease stress inputs (differential degree of stress) or due to par-
ticular cellularmechanisms that generate increased resistance
to cellular stress. In conclusion, regardless of the cause of
motoneuron stress, it is becoming evident that modulation
of protein folding stress or the proteostatic capacity of
motoneurons may represent a potent therapeutic target to
delay the symptomatic phase of ALS. In this context, the use
of gene therapy or small molecules to reinforce the stress
response capacity is becoming an interesting tool for disease
intervention (Figure 4(c)).
In order to understand the contribution of ER stress and
the UPR to ALS, many groups have manipulated UPR com-
ponents and studied the evolution of the disease (Figure 2).
The deficiency of the ER stress-related proapoptotic genes
ask1, puma, or bim delays ALS in mouse models, possibly by
rescuing motoneuron viability [37, 55, 56]. We investigated
if deficiency of the transcription factor XBP1 could have an
impact on ALS progression by crossbreeding a conditional
knockout mouse for XBP1 in the nervous system [57] with
transgenic mouse overexpressing mutant SOD1 [31]. Unex-
pectedly, despite predictions that deletion of this important
UPR component would enhance the severity of experimental
ALS (i.e., impaired adaptation to ER stress), we observed that
the SOD1 mutant offspring that were knockout for XBP1 in
the nervous system had delayed disease onset. These effects
were associated with reduced accumulation of mutant SOD1
aggregates in vivo and in cell culture models and enhanced
autophagy levels [31]. In agreement with this concept, we
and others have recently reported that the pharmacological
activation of autophagy can improve the survival and disease
signs of mouse models of ALS, an effect associated with the
clearance of abnormal protein aggregates [58, 59].These find-
ings can be contrasted with the unexpected results obtained
from the treatment of the mutant SOD1 mice with another
autophagy inductor, rapamycin, in which an accelerated
progression of the disease was observed [60]. These results
may be explained by the fact that the rapamycin target,mTOR
(mammalian target of rapamycin), is involved in diverse cel-
lular processes such as regulation of mRNA translation, cell
metabolism, and inflammation, among others [61]. Despite
these divergent results, autophagy represents an interesting
target for future therapeutic development.
Other studies have validated a functional contribution
of the UPR to ALS with unexpected results (Figure 2).
Remarkably, a treatment of mutant SOD1 transgenic mice
with salubrinal [52], a small molecule that enhances eIF2𝛼
phosphorylation [62], led to significant protection against
experimental ALS progression [52]. Consistent with this
report, perk haploinsufficiency (perk+/− mice) exacerbated
the severity of experimental ALS, decreasing life span. This
phenotype was associated with exacerbated neuronal loss
and enhanced mutant SOD1 aggregation [43]. In this study,
however, the loss of one perk allele did not decrease the
induction of ATF4 at the early symptomatic stage and
only partially reduced ATF4 levels at the end stage of the
disease [43]. In agreement with this observation the levels
of ATF-4 target genes, such chop and bip were not altered
in PERK+/−/SOD1mutant mice [43]. These studies suggest
that the effects attributed to perk haploinsufficiency in ALS
pathogenesis are mostly related to the inhibition of protein
translation through eIF2𝛼 phosphorylation and not due to
ATF4 induction.
We also have recently reported the impact of targeting
the transcription factor ATF4 in ALS in vivo using a full
knockoutmodel. Unexpectedly, ATF4 deficiency reduced the
probability of the birth of mutant SOD1 mice, suggesting
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Figure 2: Targeting the UPR in ALS. Different factors may induce ER dysfunction in ALS. For example, abnormal protein aggrega-
tion/misfolding, PDIs inactivation by nitrosylation, ERAD dysfunction, altered vesicle traffic, and/or autophagy defects represent conditions
that could induce ER stress and lead to an adaptive stress response known as the unfolded protein response (UPR) at early disease stages.The
manipulation of different UPR components has revealed a functional contribution of distinct ER stress signaling events in preclinical models
of ALS. Genetic targeting of ASK1 (ASK1−/−), a downstream signaling component of IRE1𝛼, protects against the development of experimental
ALS decreasing motor neuron death in the spinal cord of mutant SOD1G93A mice [56]. The deletion in the CNS of the transcription factor
XBP1 (CNS XBP1−/−) increases the survival of the mutant SOD1G86R mice, associated with reduced accumulation of mutant SOD1 aggregates
in vivo and enhanced autophagy levels [31]. PERK haploinsufficiency (PERK+/−) enhanced the severity of experimental ALS, associated with
elevated levels of neuronal loss and mutant SOD1 aggregation [43]. The deletion of the transcription factor ATF4 (ATF4−/−) in the SOD1G86R
mutant mice delays the appearance of the symptoms and the extended animal survival. These effects were associated to changes in the ER
protein folding network and apoptotic genes [63]. In a pharmacological strategy, the treatment of mutant SOD1 mice with a small molecule
that selectively induces eIF2𝛼 phosphorylation, salubrinal, protects against disease progression [52]. No manipulation of ATF6 in animal
models of ALS has been described.
that the UPR may even contribute to mitigating pathological
stress during development in this model [63]. On the other
hand, the ATF4 knockout/mutant SOD1 transgenic mice that
were born showed delayed disease onset and prolonged life
span [63]. Consistent with the role of ATF4 in apoptosis,
its deficiency completely ablated the induction of BIM and
CHOP in mutant SOD1 mice, in addition to induced quan-
titative changes in the protein homeostasis network. Con-
versely, ATF4 deficiency enhanced mutant SOD1 misfolding
at the end stage of the disease. Thus, PERK signaling may
have differential and contrasting effects on ALS pathogenesis,
in which eIF2𝛼 phosphorylation affords protection whereas
ATF4 induction may trigger motoneuron apoptosis.
Although the activation of UPR has not been entirely
described in animal models expressing TDP-43 mutant pro-
teins [64], in a recent study, the use of drugs to alleviate ER
stress showed significant protection against the neurotoxicity
induced by mutant TDP-43 in worm and zebrafish models of
ALS [65]. The treatment of these animal models with salu-
brinal or guanabenz, two drugs that sustain eIF2𝛼 phospho-
rylation by different mechanisms [62, 66], reduced toxicity
and improvedmotility ofworms andfishes expressingmutant
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TDP-43 [65]. These results, together with those obtained
from pharmacological intervention of eIF2𝛼 in mutant SOD1
mouse models, support the idea that ER stress is a main
event inALS. In summary, these studies illustrate the complex
nature of UPR signaling in ALS, clearly demonstrating that
targeting specific components of the pathway may have
distinct consequences on disease progression [12]. These
studies have identified some of the components of the UPR
as a potential target to treat ALS.
6. A Role of the Glia and
Oligodendrocyte UPR in ALS?
Theextracellular environment can influencemotoneuron fate
in the context of ALS as depicted by the interplay between
motoneurons and the glia. For example, it is possible to
induce ALS pathology in mice overexpressing mutant SOD1
in nonneuronal cells [67]. In cellular assays, supernatant
derived from astrocytes/motoneuron cocultures of mutant
SOD1 transgenicmice can trigger neuronal death ofwild-type
neuronal cultures. The toxic factors released from mutant
SOD1 primary cells are able to induce hyperexcitability and
subsequent cell death [68].
Several studies have shown that the expression of mutant
SOD1 in astrocytes or microglia regulates the progression of
ALS (see examples in [69–71]). A recent study showed that
UPR activation also takes place in these glial cells [72]. ER
stress markers can be observed particularly in microglia even
at early stages of the disease. These results support the idea
that UPR may have a broad impact on noncell autonomous
aspects of ALS [72].
Recent reports suggest that oligodendrocytes may also
play a relevant role in ALS. Extensive degeneration was
reported in the gray matter oligodendrocytes in the spinal
cord of mutant SOD1 mice prior to the appearance of disease
signs [73]. Similar results were observed in ALS human post-
mortem tissue [74]. Although new oligodendrocytes were
formed, they did not mature and were unable to mediate
remyelination. Of note, great advances have been obtained
in understanding the role of ER stress in oligodendrocytes in
models of multiple sclerosis, where inflammatory reactions
trigger demyelination andmotoneuron degeneration [75, 76].
IFN-𝛾-dependent activation of the PERK pathway in oligo-
dendrocytes was protective in a mouse model of multiple
sclerosis [77]. Moreover, salubrinal also protected against
disease progression in the same model [78]. A recent paper
confirmed the protective role of PERK pathway against
cytotoxic events using a temporally controlled activation
of PERK in oligodendrocytes of an experimental model of
multiple sclerosis [79]. Similarly, we have recently reported
a reduced locomotor recovery in ATF4 or XBP1 knockout
models after a spinal cord injury. In addition, gene therapy
to deliver active XBP1 into the spinal cord had a significant
impact on motor recovery after spinal cord injury which was
associated with enhanced oligodendrocyte survival [80].This
is an important finding considering the close relationship of
glia and neurons and a possible coordinated/associated stress
response between both cell types. These results support the
notion that modulating the UPR in a non-cell autonomous
manner may also represent an interesting strategy to attenu-
ate ALS progression. This idea remains to be tested.
7. The PDI Family of Proteins and ALS
At the early stages of the UPR activation, the folding capacity
of the ER is increased through the up-regulation of the ER
chaperons such as BiP/Grp78, Grp94, calreticulin (CRT),
calnexin (CNX), and several members of the protein disul-
fide isomerase (PDI) family [81]. These events reduce ER
stress levels by enhancing the folding capacity of the ER
or by removing terminally misfolded proteins through ER-
associated degradation (ERAD) [82]. In the last years, the
role of ER resident chaperons and foldases, in particular some
members of the PDI family, has gained an important place in
the ALS field. Here we discuss most relevant data revealing a
participation of these proteins in the ALS.
A recent genetic screening revealed associations of PDIA1
intronic variants as a risk factor to develop ALS [83].
However, nomechanistic studies were provided to determine
the possible impact of these genetic alterations on the disease.
PDIs are a large protein family comprised of 21 known
members of the thioredoxin superfamily, classified based on
sequence and structural homology (reviewed in [84]). Most
PDIs have a foldase function and catalyzed disulfide bond
formation and, as wewill discuss later, can also inhibit protein
aggregation and modulate cell viability. Of note, several PDI
family members have been involved in neurodegenerative
disease such as Parkinson’s disease, Alzheimer’s Disease,
prion-related disorders, and Huntington’s disease (review in
[85]). Importantly, a proteomic analysis of spinal cord tissue
of mutant SOD1 mice reporting PDIA1 and ERp57 (also
known as Grp58 or PDIA3) as major up-regulated proteins
was the first study suggesting a possible participation of
PDIs in ALS [86]. These results were later confirmed by
independent study [87].
Mutant SOD1 has been shown to accumulate in the ER
in vivo [38, 86]. In addition, the translocation of SOD1 to
microsomal fractions has been reconstituted in vitro with
purified components [88]. Mutant SOD1 is also secreted to
the extracellular space through a classical Golgi-dependent
mechanism [41]. Atkin et al. reported a physical interaction
between the wild-type and mutant SOD1 and PDIA1 in
vivo [86]. They also showed a colocalization of PDIA1 with
mutant SOD1 inclusions. This was also observed in spinal
cord samples from ALS patients [32, 89]. Similarly, mutant
SOD1 was shown to interact with the ER chaperone BiP in
the spinal cord of mutant SOD1 transgenic mice [38]. At the
functional level, PDIA1 overexpression in cell culture reduced
mutant SOD1 aggregation, ER stress, and also induced cell
death [90]. In contrast, the inhibition of PDI with the
antibiotic bacitracin [91] increased mutant SOD1 inclusions
[86], suggesting that PDIA1 prevents the formation of SOD1
aggregates. Similarly, TDP-43 positive inclusions have been
shown to colocalize with PDAI1 in sALS samples [89]. ALS-
linked FUS mutant has been also shown to induce ER stress,
colocalizing with PDIA1 in cell culture and spinal cord tissue
from sALS and fALS cases, in addition to animal models of
the disease [92]. Moreover, a physical association between
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mutant FUS and PDIA1 was reported [92]. It is still unknown
if the manipulation of PDI levels will a ect the progression of
experimental ALS in vivo.
Modification and inactivation of PDIA1 were also
reported in spinal cord tissue from sALS and mouse mod-
els of the disease [90]. Similar observations were also
described before in brain tissue derived from Parkinson’s and
Alzheimer’s disease patients [93]. It was proposed through
cell culture studies that PDI nitrosylation may contribute
to the disease by inhibiting the protective roles attributed
to these foldases. This abnormal modification of PDI could
result from altered nitric oxide synthase activity found in
mousemodels of the disease [94]. Although PDIs are thought
to have a neuroprotective activity, one report suggested that
PDIA1 and ERp57 may actually have a pro-apoptotic activ-
ity in models of Alzheimer and Huntington’s disease [95].
Accordingly, UPR activation in microglia correlated with
an increase of PDIA1 protein and neurotoxicity [72]. These
data suggest that future therapeutic manipulation of the UPR
should examine in more detail its impact on glial cells.
The formation of disulfide bonds by PDIs inside the ER
requires specific redox conditions and fine balance between
the oxidized and reduced states of PDIs [96–100]. The ER
is an extremely oxidizing environment compared with the
cytoplasm, and the maintenance of its redox state relies on
PDI activity of the formation of the disulfide bonds. The
generation of disulfide bonds is highly regulated and involves
the enzyme ERO1, which is an important oxidase for disulfide
formation [101]. The perturbation of the redox status of the
ER is deleterious for the proper cell function and there are
tight mechanisms to buffer the possible redox fluctuations
[102]. We have recently described that ATF4 deficiency alters
the redox status of the cell and also the ER as measured by
monitoring H
2
O
2
levels, a subproduct of the PDI/ERO1 cycle
[63]. Of note, the treatment of motoneuron cells with the
antioxidant trolox is able to revert the enhanced aggregation
of mutant SOD1 observed after knocking down ATF4. In
addition, overexpression of ERO1 also modulated mutant
SOD1 aggregation [63], suggesting that the manipulation of
ER redox state can impact the misfolding of mutant SOD1.
Taken together, these data suggest that PDIs may play a
significant role in ALS by affecting different aspects of cell
physiology including protein aggregation, cell survival, and
the redox status of the ER (Figure 3).
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Figure 4: ER stress and the selective neuronal vulnerability in ALS. (a) Schematic representation of ER stress levels (green label) and UPR
activation (purple label) in the two subgroups of neurons that have been identified in mutant SOD1 mouse models of ALS: one population
that dies early (vul, vulnerable, blue) and another that dies later during disease progression (res, resistant, red). Activation of stress markers is
a common feature detected in Vul and Res motoneurons. However, vul motoneurons express these stress markers earlier than de res neurons.
The UPR is activated in both subgroups of neurons. UPR activation also correlates with microglial activation in both groups. It is not known
what determines the resistance of Res cells in the disease. (b) Time-course of ER stress levels and UPR activation in familial ALS models. ER
stress and protein disturbance increase during ALS progression (“ER dysfunction,” black dashed line). During the presymptomatic stage of
the disease, UPR activation might represent an adaptive response that attenuates ER stress levels. Over time, the stress condition exceeds the
capacity of the cell to manage protein folding stress and pro-apoptotic pathways are activated. This shift “onset threshold” in UPR signaling
regulation could be associated with motoneuron dysfunction/loss and the onset of the disease. During the symptomatic stage, a strong and
chronic UPR activation occurs. (c) Possible therapeutic approaches to modulate the UPR in ALS. An earlystage preventive treatment may
modulate UPR levels to enhance the adaptive capacity of motoneurons and reduce ER stress levels or other proteostasis disturbances. This
may delay disease onset and disease evolution “healthy window”. The therapeutic approaches include gene therapy to deliver active UPR
components and the use of smallmolecules that selectively activate specific UPR signaling branches (pharmacologic approaches) or act as
chemical chaperones to alleviate global ER stress. This reduction in ER stress levels in motoneurons could also be achieved by modulating
glial UPR.
8. ER Stress Signaling in sALS: Novel
Biomarker for Disease Prognosis?
Early studies have shown that several ER chaperones can be
secreted to the extracellular space upon stress [103]. Recently,
PDIA1 levels have been reported to be up-regulated in the
cerebrospinal fluid (CSF) of ALS patients [30]. Interestingly,
Vijayalakshmi et al. showed the induction of ER stress in
spinal motor neurons exposed to CSF of sporadic ALS
patients [34]. This fact suggests that measuring stress factors
in CSF may represent an interesting tool to monitor ALS dis-
ease progression. There is a current need for biomarkers of
ALS to assess, on a quantitative manner, disease prognosis
and the efficacy of clinical trials.
In a recent proteomic screening searching for biomarkers
in blood samples from sALS patients, the up- regulation of
the ER stress-responsive chaperones PDIA1, ERp57, and other
chaperones was observed [104]. Similar changes were also
seen in mononuclear cells from blood of mutant SOD1 mice.
It was demonstrated that TDP-43, cyclophilin A, and ERp57
are strongly associated with disease course in a longitudinal
study in ALS patients and control subjects, ERp57 having
the best score [104]. These two studies open the interesting
possibility of monitoring stress signatures to diagnose and
monitor progression of ALS.
9. Perspective
ER dysfunction is currently viewed as a relevant factor
driving diverse diseases of the nervous system, representing
an important niche for drug discovery. Due to the fact that the
type, intensity, and temporality of ER stress stimuli determine
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how the UPR integrates information towards controlling
cell fate, this pathway offers interesting targets to modulate
both cell survival and death mechanisms. Depending on the
disease context, targeting strategies may involve attenuation
of ER stress levels, inactivation of pro-apoptotic components
of the UPR, or the enhancement of UPR signaling responses
toward adaptation to stress (Figure 4). The scenario in ALS
is very complex. Genetic and pharmacological manipulation
of the pathway in preclinical models of the disease supports
the idea that the UPR may contribute to both cell viability
of stressed cells and also the elimination of motoneurons
when there is irreversible damage. More research is needed
to understand the consequence of manipulating the UPR to
validate the pathway as a target. For such step, it is essential to
define the optimal targets to alleviate ER stress inALS. Impor-
tantly, it is becoming clear that sporadic and familial ALS,
regardless of the specific genetic alteration, may converge
into alterations on ER function, offering unique therapeutic
opportunities. The fact that mutations in PDIA1 gene were
recently described in ALS patients suggests a causative role of
proteostasis defects at the ER. Supporting this notion, muta-
tions in two important proteins involved in the degradation of
misfolded proteins, Ubiquilin1 [105] and p62 [106], have been
found in ALS cases. Predicting and defining the possible side
effects ofmanipulating theUPR at the systemic levels remains
an important subject for future validation of the pathway
as a drug target and move forward into the development of
human therapies.
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